Miniaturized receptor binding assays: Complications arising from ligand depletion

被引:50
作者
Carter, Clare M. Scaramellini
Leighton-Davies, Juliet R.
Charlton, Steven J. [1 ]
机构
[1] UCB, Cambridge, England
[2] Novartis Inst Biomed Res Inc, Cambridge, MA USA
关键词
ligand depletion; binding assay; miniaturization; radioligand;
D O I
10.1177/1087057106297788
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The advent of miniaturized assay formats has made possible the screening of large numbers of compounds against a single target, known as high-throughput screening. Despite this clear advantage, assay miniaturization also increases the risk of ligand depletion, where the actual concentration of free ligand is significantly lower than that added. This, in turn, complicates the interpretation of data from such assays, potentially introducing significant error if not recognized. In this study, the effects of reducing assay volume on radioligand Kd and competitor Ki values have been investigated, using the muscarinic M, receptor as a model system. It was found that assay miniaturization caused dramatic effects, with LIP to a 30-fold underestimation of ligand affinity. A theoretical model was developed and shown to accurately predict both the degree of ligand depletion in any given assay volume and the effect of this depletion on affinity estimates for competing ligands. Importantly, it was found that in most cases, errors introduced by ligand depletion could be largely corrected for by the use of appropriate analysis methods. In addition to those previously described by others, the authors propose a simple method capable of correcting errors in competition binding experiments performed in conditions of ligand depletion.
引用
收藏
页码:255 / 266
页数:12
相关论文
共 15 条
[1]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[2]   QUANTITATIVE ASPECTS OF HORMONE-RECEPTOR INTERACTIONS OF HIGH AFFINITY - EFFECT OF RECEPTOR CONCENTRATION AND MEASUREMENT OF DISSOCIATION-CONSTANTS OF LABELED AND UNLABELED HORMONES [J].
CHANG, KJ ;
JACOBS, S ;
CUATRECASAS, P .
BIOCHIMICA ET BIOPHYSICA ACTA, 1975, 406 (02) :294-303
[3]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[4]  
CLARK AJ, 1933, MODE ACTION DRUGS CA
[5]  
DOWLING MR, 2006, BRIT J PHARMACOL, V148, P97
[6]  
Gaddum J.H, 1937, J PHYSL CAMBRIDGE K, V89, P7
[7]  
GOLDSTEIN A, 1987, MOL PHARMACOL, V31, P603
[8]  
Hill AV, 1909, J PHYSIOL-LONDON, V39, P361
[9]  
HULME EC, 1992, RECEPTOR LIGAND INTE, P63
[10]  
Motulsky H. J., 2003, FITTING MODELS BIOL, DOI DOI 10.1007/BFB0067700